Cerenis reports top-line phase II results for its HDL mimetic CER-001

Cerenis Therapeutics, the biopharmaceutical company, has announced that its Phase IIb CHI-SQUARE (Can HDL Infusions Significantly Quicken Atherosclerosis REgression?) study did not reach its primary endpoint in post-Acute Coronary Syndrome (ACS) patients.The Phase IIb efficacy and safety trial randomized 507 patients with ACS at 53 centers in the US, Canada, France and The Netherlands. via Health News from Medical News Today Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2014/01/cerenis-reports-top-line-phase-ii.html